Bent Ejlertsen

22.7k total citations · 1 hit paper
252 papers, 6.4k citations indexed

About

Bent Ejlertsen is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Bent Ejlertsen has authored 252 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Oncology, 152 papers in Cancer Research and 88 papers in Genetics. Recurrent topics in Bent Ejlertsen's work include Breast Cancer Treatment Studies (124 papers), HER2/EGFR in Cancer Research (72 papers) and Cancer Treatment and Pharmacology (61 papers). Bent Ejlertsen is often cited by papers focused on Breast Cancer Treatment Studies (124 papers), HER2/EGFR in Cancer Research (72 papers) and Cancer Treatment and Pharmacology (61 papers). Bent Ejlertsen collaborates with scholars based in Denmark, United States and United Kingdom. Bent Ejlertsen's co-authors include Maj‐Britt Jensen, Henning T. Mouridsen, Peer Christiansen, Ann Knoop, Niels Kroman, Birgitte Rasmussen, Eva Balslev, Kirsten Vang Nielsen, Anne‐Vibeke Lænkholm and Deirdre Cronin‐Fenton and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Bent Ejlertsen

242 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis

2021 189 citations Lene Mellemkjær, Peer Christiansen et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bent Ejlertsen Denmark	44	3.9k	2.8k	1.5k	1.3k	1.2k	252	6.4k
Tommy� Fornander Sweden	45	2.9k 0.7×	2.6k 0.9×	2.1k 1.4×	1.2k 0.9×	1.2k 1.0×	133	6.5k
Jacques Bonneterre France	44	5.1k 1.3×	2.8k 1.0×	1.5k 1.0×	1.9k 1.5×	1.7k 1.4×	257	8.0k
J.W.R. Nortier Netherlands	44	3.5k 0.9×	1.9k 0.7×	982 0.7×	952 0.7×	1.2k 1.0×	157	7.8k
Agnes Jager Netherlands	46	2.5k 0.6×	1.7k 0.6×	1.1k 0.7×	1.4k 1.1×	1.2k 1.0×	227	7.0k
Kamila Czene Sweden	44	3.2k 0.8×	2.0k 0.7×	1.6k 1.1×	1.3k 1.0×	1.7k 1.4×	261	7.1k
Boštjan Šeruga Canada	34	4.4k 1.1×	1.6k 0.6×	786 0.5×	1.2k 0.9×	1.8k 1.5×	124	7.4k
Gershon Y. Locker United States	30	6.1k 1.6×	3.0k 1.0×	2.1k 1.4×	2.2k 1.7×	1.8k 1.5×	76	9.5k
Stefan Aebi Switzerland	38	4.2k 1.1×	3.1k 1.1×	909 0.6×	2.3k 1.8×	1.2k 1.0×	141	7.8k
Ivana Šestak United Kingdom	36	4.1k 1.1×	4.1k 1.4×	3.3k 2.2×	1.4k 1.1×	1.4k 1.1×	108	7.7k
Sei Hyun Ahn South Korea	36	2.2k 0.6×	1.9k 0.7×	758 0.5×	952 0.7×	639 0.5×	238	4.7k

Countries citing papers authored by Bent Ejlertsen

Since Specialization

Citations

This map shows the geographic impact of Bent Ejlertsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bent Ejlertsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bent Ejlertsen more than expected).

Fields of papers citing papers by Bent Ejlertsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bent Ejlertsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bent Ejlertsen. The network helps show where Bent Ejlertsen may publish in the future.

Co-authorship network of co-authors of Bent Ejlertsen

This figure shows the co-authorship network connecting the top 25 collaborators of Bent Ejlertsen. A scholar is included among the top collaborators of Bent Ejlertsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bent Ejlertsen. Bent Ejlertsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berg, Tobias, Lise Barlebo Ahlborn, Maj‐Britt Jensen, et al.. (2025). Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer. Neoplasia. 63. 101162–101162.

Borgquist, Signe, Maj‐Britt Jensen, Peer Christiansen, et al.. (2025). Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo. Clinical Epidemiology. Volume 17. 409–419. 4 indexed citations

Pedersen, Rikke Neess, Mette Nørgaard, Lene Mellemkjær, et al.. (2025). Association between low-dose aspirin use and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up. British Journal of Cancer. 133(6). 865–873.

Jensen, Maj‐Britt, Bent Ejlertsen, Mads Thomassen, et al.. (2025). Germline BRCA testing in Denmark following invasive breast cancer: Progress since 2000. Acta Oncologica. 64. 147–155. 1 indexed citations

Berg, Tobias, Maj‐Britt Jensen, Maria Rossing, et al.. (2024). Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer. JAMA Network Open. 7(3). e242174–e242174. 4 indexed citations

Bojesen, Stig E., Julia S. Johansen, Bent Ejlertsen, et al.. (2024). Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 33(5). 662–670. 1 indexed citations

Schmidt, Julie A., et al.. (2024). Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer. Journal of Clinical Oncology. 42(28). 3300–3307. 10 indexed citations

Jensen, Maj‐Britt, Christina B. Pedersen, L.J. Gibson, et al.. (2023). Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: a Copenhagen Breast Cancer Genomics Study. npj Breast Cancer. 9(1). 47–47. 4 indexed citations

Cold, Søren, Frederik Cold, Maj‐Britt Jensen, et al.. (2022). Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. JNCI Journal of the National Cancer Institute. 114(10). 1347–1354. 57 indexed citations

10.

Stovgaard, Elisabeth Specht, Maj‐Britt Jensen, Karama Asleh, et al.. (2022). Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial. Cancers. 14(15). 3808–3808. 2 indexed citations

11.

Hurvitz, Sara A., Nicholas P. McAndrew, Aditya Bardia, et al.. (2021). A careful reassessment of anthracycline use in curable breast cancer. npj Breast Cancer. 7(1). 134–134. 33 indexed citations

12.

Hviid, Thomas Vauvert F., Jens Ole Eriksen, Bent Ejlertsen, et al.. (2021). Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. British Journal of Cancer. 125(10). 1388–1398. 11 indexed citations

13.

Collin, Lindsay J., Deirdre Cronin‐Fenton, Thomas P. Ahern, et al.. (2021). Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women. Clinical Cancer Research. 27(5). 1421–1428. 33 indexed citations

14.

Karlsen, Mona Aarenstrup, Lone Storgaard, Niels Kroman, et al.. (2021). Survival in Women Diagnosed With Breast Cancer During Pregnancy. Clinical Breast Cancer. 22(4). e517–e525. 5 indexed citations

15.

Møller, Tom, Christina Andersen, Christian Lillelund, et al.. (2020). Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial. Scientific Reports. 10(1). 9710–9710. 33 indexed citations

16.

Leone, José Pablo, Bernard F. Cole, Meredith M. Regan, et al.. (2020). Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial. Cancer. 127(5). 700–708. 5 indexed citations

17.

Ahern, Thomas P., Lindsay J. Collin, James W. Baurley, et al.. (2020). Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients. Cancer Epidemiology Biomarkers & Prevention. 29(3). 582–590. 7 indexed citations

18.

Jensen, Maj‐Britt, Lisbet Rosenkrantz Hölmich, Anne Bodilsen, et al.. (2020). Rates of re-excision and conversion to mastectomy after breast-conserving surgery with or without oncoplastic surgery: a nationwide population-based study. British journal of surgery. 107(13). 1762–1772. 27 indexed citations

19.

Cronin‐Fenton, Deirdre, Uffe Heide‐Jørgensen, Thomas P. Ahern, et al.. (2016). Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence. Epidemiology. 27(4). 586–593. 28 indexed citations

20.

Ewertz, Marianne, Kathryn P. Gray, Meredith M. Regan, et al.. (2012). Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial. Journal of Clinical Oncology. 30(32). 3967–3975. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact